Previous study already proved that targeting HBP sensitizes pancreatic cancer to anti-PD1 therapy in pancreatic cancer (35), and O-GlcNAcylation inhibition activates T cell-mediated antitumor immunity in vitro (36). The gene discussed is PDCD1; the disease is familial pancreatic carcinoma.